

Brenda F Kurland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5109587/publications.pdf>

Version: 2024-02-01

111
papers

6,708
citations

57631

44
h-index

64668

79
g-index

112
all docs

112
docs citations

112
times ranked

9750
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. <i>Neurobiology of Aging</i> , 2009, 30, 1026-1036.	1.5	558
2	Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. <i>Blood</i> , 2011, 117, 4651-4657.	0.6	319
3	Quantitative imaging biomarkers: A review of statistical methods for technical performance assessment. <i>Statistical Methods in Medical Research</i> , 2015, 24, 27-67.	0.7	272
4	Quantitative Diffusion-Weighted Imaging as an Adjunct to Conventional Breast MRI for Improved Positive Predictive Value. <i>American Journal of Roentgenology</i> , 2009, 193, 1716-1722.	1.0	246
5	Misspecified maximum likelihood estimates and generalised linear mixed models. <i>Biometrika</i> , 2001, 88, 973-985.	1.3	234
6	Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1415-1421.	0.8	180
7	SHELL: Oral Language and Early Literacy Skills in Kindergarten and First-Grade Children. <i>Journal of Research in Childhood Education</i> , 1995, 10, 37-48.	0.6	171
8	Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2016, 22, 1130-1137.	3.2	166
9	BI-RADS Lesion Characteristics Predict Likelihood of Malignancy in Breast MRI for Masses But Not for Nonmasslike Enhancement. <i>American Journal of Roentgenology</i> , 2009, 193, 994-1000.	1.0	150
10	Differential diagnosis of mammographically and clinically occult breast lesions on diffusion-weighted MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2010, 31, 562-570.	1.9	148
11	Longitudinal Data with Follow-up Truncated by Death: Match the Analysis Method to Research Aims. <i>Statistical Science</i> , 2009, 24, 211.	1.6	145
12	Apparent Diffusion Coefficient Values for Discriminating Benign and Malignant Breast MRI Lesions: Effects of Lesion Type and Size. <i>American Journal of Roentgenology</i> , 2010, 194, 1664-1673.	1.0	145
13	Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4449-4457.	0.8	142
14	The Burden and Patterns of Disability in Activities of Daily Living Among Community-living Older Persons. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2003, 58, M70-M75.	1.7	123
15	Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 4799-4805.	3.2	120
16	Race/ethnic differences in AD survival in US Alzheimer's Disease Centers. <i>Neurology</i> , 2008, 70, 1163-1170.	1.5	118
17	Prospective Neurocognitive Function Over 5 Years After Allogeneic Hematopoietic Cell Transplantation for Cancer Survivors Compared With Matched Controls at 5 Years. <i>Journal of Clinical Oncology</i> , 2011, 29, 2397-2404.	0.8	113
18	Sexual function changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 years. <i>Blood</i> , 2008, 111, 989-996.	0.6	111

#	ARTICLE	IF	CITATIONS
19	Directly parameterized regression conditioning on being alive: analysis of longitudinal data truncated by deaths. <i>Biostatistics</i> , 2005, 6, 241-258.	0.9	108
20	Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring <i>BRAF</i> mutations in the <i>Lung Cancer Mutation Consortium</i> . <i>Cancer</i> , 2015, 121, 448-456.	2.0	102
21	Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. <i>Blood</i> , 2012, 120, 2545-2552.	0.6	101
22	Serial 2-[¹⁸ F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). <i>Breast Cancer Research and Treatment</i> , 2007, 105, 87-94.	1.1	97
23	Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes. <i>Annals of Thoracic Surgery</i> , 2008, 86, 1632-1639.	0.7	96
24	A 3-dimensional analysis of molar movement during headgear treatment. <i>American Journal of Orthodontics and Dentofacial Orthopedics</i> , 2002, 121, 18-29.	0.8	95
25	PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake. <i>Clinical Cancer Research</i> , 2011, 17, 2400-2409.	3.2	94
26	Education, cognitive function, and severity of neuropathology in Alzheimer disease. <i>Neurology</i> , 2008, 70, 1732-1739.	1.5	91
27	Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 407-415.	3.2	88
28	Improved diagnostic accuracy of breast MRI through combined apparent diffusion coefficients and dynamic contrast-enhanced kinetics. <i>Magnetic Resonance in Medicine</i> , 2011, 65, 1759-1767.	1.9	86
29	Quantitative assessment of dynamic PET imaging data in cancer imaging. <i>Magnetic Resonance Imaging</i> , 2012, 30, 1203-1215.	1.0	84
30	Validation of Measurement Scales in Ocular Graft-versus-Host Disease. <i>Ophthalmology</i> , 2012, 119, 487-493.	2.5	83
31	Promise and pitfalls of quantitative imaging in oncology clinical trials. <i>Magnetic Resonance Imaging</i> , 2012, 30, 1301-1312.	1.0	83
32	A Phase 2 Study of ¹⁶ β-[¹⁸ F]-fluoro- ¹⁷ β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC). <i>Molecular Imaging and Biology</i> , 2014, 16, 431-440.	1.3	80
33	Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or <i>BRCA</i> Mutation-Associated Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2855-2864.	3.2	80
34	Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 337-344.	2.0	76
35	Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 2803-2810.	3.2	72
36	Talking and reading science: Longitudinal data on sex differences in mother-child conversations in low-income families. <i>Journal of Applied Developmental Psychology</i> , 2005, 26, 1-19.	0.8	65

#	ARTICLE	IF	CITATIONS
37	Between-Patient and Within-Patient (Site-to-Site) Variability in Estrogen Receptor Binding, Measured In Vivo by ^{18}F -Fluoroestradiol PET. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1541-1549.	2.8	65
38	Factors influencing the uptake of ^{18}F -fluoroestradiol in patients with estrogen receptor positive breast cancer. <i>Nuclear Medicine and Biology</i> , 2011, 38, 969-978.	0.3	62
39	Dynamic and Static Approaches to Quantifying ^{18}F -FDG Uptake for Measuring Cancer Response to Therapy, Including the Effect of Granulocyte CSF. <i>Journal of Nuclear Medicine</i> , 2007, 48, 920-925.	2.8	61
40	Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with $^{16}\alpha\text{-}^{18}\text{F}$ -Fluoro- $^{17}\beta\text{-}^2$ -Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications. <i>Oncologist</i> , 2020, 25, 835-844.	1.9	60
41	ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. <i>British Journal of Cancer</i> , 2013, 109, 2096-2105.	2.9	53
42	Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1843-1849.	2.8	52
43	Prognostic Effect of Prior Disability Episodes among Nondisabled Community-living Older Persons. <i>American Journal of Epidemiology</i> , 2003, 158, 1090-1096.	1.6	51
44	Assessment of Joint and Fascia Manifestations in Chronic Graft-versus-Host Disease. <i>Arthritis and Rheumatology</i> , 2014, 66, 1044-1052.	2.9	50
45	Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium. <i>Haematologica</i> , 2011, 96, 1528-1535.	1.7	48
46	Internal Mammary Nodal Chain Drainage Is a Prognostic Indicator in Axillary Node-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2007, 14, 2985-2993.	0.7	44
47	Analysis of Gastrointestinal and Hepatic Chronic Graft-versus-Host Disease Manifestations on Major Outcomes: A Chronic Graft-versus-Host Disease Consortium Study. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 784-791.	2.0	43
48	Association between serial dynamic contrast-enhanced MRI and dynamic ^{18}F -FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2010, 32, 1124-1131.	1.9	41
49	Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium. <i>Bone Marrow Transplantation</i> , 2013, 48, 1123-1128.	1.3	41
50	Parametric Response Mapping of Apparent Diffusion Coefficient as an Imaging Biomarker to Distinguish Pseudoprogression from True Tumor Progression in Peptide-Based Vaccine Therapy for Pediatric Diffuse Intrinsic Pontine Glioma. <i>American Journal of Neuroradiology</i> , 2015, 36, 2170-2176.	1.2	41
51	Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 793-804.	1.9	41
52	Nondaily Smokers™ Changes in Cigarette Consumption With Very Low-Nicotine-Content Cigarettes. <i>JAMA Psychiatry</i> , 2018, 75, 995.	6.0	39
53	Longitudinal measurement of growth in definitional skill. <i>Journal of Child Language</i> , 1997, 24, 603-625.	0.8	35
54	ATM protein is deficient in over 40% of lung adenocarcinomas. <i>Oncotarget</i> , 2016, 7, 57714-57725.	0.8	35

#	ARTICLE	IF	CITATIONS
55	Metabolic and Vascular Features of Dynamic Contrast-enhanced Breast Magnetic Resonance Imaging and 15O-Water Positron Emission Tomography Blood Flow in Breast Cancer. <i>Academic Radiology</i> , 2008, 15, 1246-1254.	1.3	34
56	External Beam Radiation Therapy and Abiraterone in Men With Localized Prostate Cancer: Safety and Effect on Tissue Androgens. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 236-243.	0.4	34
57	Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence. <i>Journal of Biological Chemistry</i> , 2018, 293, 1794-1809.	1.6	34
58	Lung Cancer Risk Prediction Using Common SNPs Located in GWAS-Identified Susceptibility Regions. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1538-1545.	0.5	33
59	Design Considerations for using PET as a Response Measure in Single Site and Multicenter Clinical Trials. <i>Academic Radiology</i> , 2012, 19, 184-190.	1.3	30
60	The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1219-1235.	0.4	30
61	Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. <i>EJNMMI Research</i> , 2012, 2, 34.	1.1	27
62	Probability of malignancy for lesions detected on breast MRI: a predictive model incorporating BI-RADS imaging features and patient characteristics. <i>European Radiology</i> , 2011, 21, 1609-1617.	2.3	26
63	Phase II Study of Systemic High-dose Methotrexate and Intrathecal Liposomal Cytarabine for Treatment of Leptomeningeal Carcinomatosis From Breast Cancer. <i>Clinical Breast Cancer</i> , 2019, 19, 311-316.	1.1	26
64	Radiomic Analysis: Study Design, Statistical Analysis, and Other Bias Mitigation Strategies. <i>Radiology</i> , 2022, 304, 265-273.	3.6	26
65	Longitudinal Change in Positive Affect in Community-Dwelling Older Persons. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1846-1853.	1.3	25
66	A Three-Marker FISH Panel Detects More Genetic Aberrations of AR, PTEN and TMPRSS2/ERG in Castration-Resistant or Metastatic Prostate Cancers than in Primary Prostate Tumors. <i>PLoS ONE</i> , 2013, 8, e74671.	1.1	25
67	Breast MRI contrast enhancement kinetics of normal parenchyma correlate with presence of breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 76.	2.2	25
68	Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2016, 18, 402-410.	1.3	25
69	Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 399-412.	0.5	25
70	Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib. <i>Clinical Breast Cancer</i> , 2019, 19, e283-e296.	1.1	24
71	Marginalized transition models for longitudinal binary data with ignorable and non-ignorable drop-out. <i>Statistics in Medicine</i> , 2004, 23, 2673-2695.	0.8	22
72	Preoperative and Intraoperative Sonographic Visibility of Collagen-Based Breast Biopsy Marker Clips. <i>Academic Radiology</i> , 2010, 17, 340-347.	1.3	22

#	ARTICLE	IF	CITATIONS
73	Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study. <i>Leukemia</i> , 2013, 27, 1196-1201.	3.3	21
74	Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size. <i>Journal of Nuclear Medicine</i> , 2016, 57, 226-230.	2.8	21
75	Test-Retest Reproducibility of ¹⁸ F-FDG PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local Network. <i>Journal of Nuclear Medicine</i> , 2019, 60, 608-614.	2.8	21
76	DCE-MRI Background Parenchymal Enhancement Quantified from an Early versus Delayed Post-contrast Sequence: Association with Breast Cancer Presence. <i>Scientific Reports</i> , 2017, 7, 2115.	1.6	20
77	¹⁸ F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2 ⁻ Metastatic Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 184-190.	2.8	20
78	High Epidermal Growth Factor Receptor Expression in Metastatic Colorectal Cancer Lymph Nodes May Be More Prognostic of Poor Survival Than in Primary Tumor. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 245-252.	0.6	19
79	Tumor-induced lymph node alterations detected by MRI lymphography using gadolinium nanoparticles. <i>Scientific Reports</i> , 2015, 5, 15641.	1.6	16
80	Diffusion-Weighted Breast Magnetic Resonance Imaging. <i>Journal of Computer Assisted Tomography</i> , 2016, 40, 428-435.	0.5	16
81	Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e143-e149.	1.1	15
82	Comparison of PD-L1 immunohistochemistry assays and response to PD-L1 inhibitors in advanced non-small cell lung cancer in clinical practice. <i>Histopathology</i> , 2019, 74, 269-275.	1.6	15
83	PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies. <i>Epigenetics</i> , 2020, 15, 604-617.	1.3	15
84	Insulin receptor substrate-1 deficiency drives a proinflammatory phenotype in KRAS mutant lung adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 8795-8800.	3.3	14
85	Clinical Indication and Patient Age Predict Likelihood of Malignancy in Suspicious Breast MRI Lesions. <i>Academic Radiology</i> , 2009, 16, 1281-1285.	1.3	12
86	Effect of 18F-FDG Uptake Time on Lesion Detectability in PET Imaging of Early-Stage Breast Cancer. <i>Tomography</i> , 2015, 1, 53-60.	0.8	12
87	Multicenter trials using 18F-fluorodeoxyglucose (FDG) PET to predict chemotherapy response: Effects of differential measurement error and bias on power calculations for unselected and enrichment designs. <i>Clinical Trials</i> , 2013, 10, 886-895.	0.7	11
88	18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study. <i>Breast Cancer Research</i> , 2021, 23, 88.	2.2	11
89	Circulating biomarkers in patients receiving neoadjuvant chemotherapy combined with sunitinib for locally advanced breast cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1089-1089.	0.8	8
90	Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan. <i>Gynecologic Oncology</i> , 2008, 110, 146-151.	0.6	7

#	ARTICLE	IF	CITATIONS
91	Accommodation of missing data in supportive and palliative care clinical trials. <i>Current Opinion in Supportive and Palliative Care</i> , 2012, 6, 465-470.	0.5	7
92	Do non-daily smokers compensate for reduced cigarette consumption when smoking very-low-nicotine-content cigarettes?. <i>Psychopharmacology</i> , 2018, 235, 3435-3441.	1.5	7
93	Expression of p16, ERCC1, and EGFR amplification as predictors of responsiveness of locally advanced squamous cell carcinomas of head and neck (SCCHN) to cisplatin, radiotherapy, and erlotinib: A phase II randomized trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5515-5515.	0.8	5
94	For Health-Related Quality of Life and Other Longitudinal Data, Analysis Should Distinguish Between Truncation by Death and Data Missing Because of Nonresponse. <i>Journal of Clinical Oncology</i> , 2016, 34, 4449-4449.	0.8	4
95	FDG PET and FES PET Predict PFS on Endocrine Therapyâ€™Response. <i>Clinical Cancer Research</i> , 2018, 24, 249-250.	3.2	4
96	Randomized phase II trial of cisplatin and radiotherapy with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2012, 30, 5503-5503.	0.8	3
97	Heterogeneity in Metastatic Breast Cancer 18F-Fluoroestradiol Uptake: Clinically Actionable, Biologically Illuminating?. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1210-1211.	2.8	2
98	Clinical Trial Design and Development Work Group Within the Quantitative Imaging Network. <i>Tomography</i> , 2020, 6, 60-64.	0.8	2
99	Signal enhancement ratio (SER) quantified from breast DCE-MRI and breast cancer risk. <i>Proceedings of SPIE</i> , 2015, , .	0.8	1
100	Accrual Patterns for Clinical Studies Involving Quantitative Imaging: Results of an NCI Quantitative Imaging Network (QIN) Survey. <i>Tomography</i> , 2016, 2, 276-282.	0.8	1
101	Dinner talk: Cultural patterns of sociability and socialization in family discourse. Shoshana Blum-Kulka. Mahwah, NJ: Erlbaum, 1997. PP. 306.. <i>Applied Psycholinguistics</i> , 1998, 19, 519-523.	0.8	0
102	Structural and Molecular Imaging in Cancer Therapy Clinical Trials. , 2012, , 387-412.		0
103	FDG PET and FES PET Predict PFS on Endocrine Therapyâ€™Response. <i>Clinical Cancer Research</i> , 2017, 23, 3475-3475.	3.2	0
104	Correlation of the NIH and Vienna Skin Scores with Provider and Patient-Reported Skin Changes in Chronic Graft-Versus-Host Disease (GVHD).. <i>Blood</i> , 2009, 114, 2256-2256.	0.6	0
105	Quality of Life and Chronic Gvhd Severity According to the NIH Criteria: Results From the Chronic Gvhd Consortium. <i>Blood</i> , 2010, 116, 393-393.	0.6	0
106	Change in NIH Skin Score Oâ€™3 Correlates with Provider- and Patient-Reported Skin Changes and Overall Survival: Results From the Chronic Gvhd Consortium. <i>Blood</i> , 2011, 118, 151-151.	0.6	0
107	Vorinostat to restore sensitivity to aromatase inhibitor therapy in metastatic breast cancer: A phase II clinical trial with ER imaging correlates.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS3109-TPS3109.	0.8	0
108	Quantitative measures of FDG PET after neoadjuvant chemotherapy to predict breast cancer patient survival.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1088-1088.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Gastrointestinal and Hepatic Involvement in Chronic Gvhd: An Analysis From the Chronic Gvhd Consortium. Blood, 2012, 120, 1940-1940.	0.6	0
110	Recommended Tools for Joint Chronic Graft-Versus-Host Disease: Results From the Chronic Gvhd Consortium. Blood, 2012, 120, 464-464.	0.6	0
111	A phase II study evaluating the safety and efficacy of sunitinib with weekly paclitaxel followed by doxorubicin and daily oral cyclophosphamide plus G-CSF as neoadjuvant chemotherapy (NC) for locally advanced (LABC) or inflammatory breast cancer (IBC).. Journal of Clinical Oncology, 2013, 31, 1090-1090.	0.8	0